Comments
Loading...
Evaxion Biotech Analyst Ratings and Price Targets | NASDAQ:EVAX | Benzinga
Evaxion Biotech AS has a consensus price target of $9.75 based on the ratings of 4 analysts. The high is $14 issued by HC Wainwright & Co. on April 2, 2025. The low is $6 issued by Lake Street on February 4, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Lake Street on April 2, 2025, February 20, 2025, and February 4, 2025, respectively. With an average price target of $11.33 between HC Wainwright & Co., HC Wainwright & Co., and Lake Street, there's an implied 739.51% upside for Evaxion Biotech AS from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Lake Street
Ladenburg Thalmann
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Evaxion Biotech
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/02/2025 | Buy Now | 937.04% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
| 02/20/2025 | Buy Now | 937.04% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
| 02/04/2025 | Buy Now | 344.44% | Lake Street | Thomas Flaten36% | $35 → $6 | Maintains | Buy | Get Alert |
| 02/03/2025 | Buy Now | 937.04% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
| 11/01/2024 | Buy Now | 937.04% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $140 → $140 | Reiterates | Buy → Buy | Get Alert |
| 09/26/2024 | Buy Now | 937.04% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $140 → $140 | Reiterates | Buy → Buy | Get Alert |
| 09/20/2024 | Buy Now | 937.04% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $140 → $140 | Reiterates | Buy → Buy | Get Alert |
| 08/16/2024 | Buy Now | 937.04% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $140 → $140 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2024 | Buy Now | 937.04% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $140 → $140 | Reiterates | Buy → Buy | Get Alert |
| 06/04/2024 | Buy Now | 937.04% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $140 → $140 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2024 | Buy Now | 937.04% | HC Wainwright & Co. | Swayampakula Ramakanth47% | → $140 | Reiterates | Buy → Buy | Get Alert |
| 04/02/2024 | Buy Now | 492.59% | Ladenburg Thalmann | Ahu Demir18% | → $80 | Upgrade | Neutral → Buy | Get Alert |
| 03/20/2024 | Buy Now | 937.04% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $140 → $140 | Reiterates | Buy → Buy | Get Alert |
| 02/12/2024 | Buy Now | 937.04% | HC Wainwright & Co. | Swayampakula Ramakanth47% | → $140 | Initiates | → Buy | Get Alert |
| 12/21/2023 | Buy Now | — | Ladenburg Thalmann | Ahu Demir18% | — | Downgrade | Buy → Neutral | Get Alert |
| 03/31/2023 | Buy Now | 418.52% | Lake Street | Thomas Flaten36% | $1800 → $700 | Maintains | Buy | Get Alert |
| 11/17/2022 | Buy Now | 714.81% | Oppenheimer | Jeff Jones32% | $1600 → $1100 | Maintains | Outperform | Get Alert |
| 07/18/2022 | Buy Now | 1085.19% | Oppenheimer | Jeff Jones32% | → $1600 | Assumes | → Outperform | Get Alert |
FAQ
What is the target price for Evaxion Biotech (EVAX) stock?
The latest price target for Evaxion Biotech (NASDAQ:EVAX) was reported by HC Wainwright & Co. on April 2, 2025. The analyst firm set a price target for $14.00 expecting EVAX to rise to within 12 months (a possible 885.92% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Evaxion Biotech (EVAX)?
The latest analyst rating for Evaxion Biotech (NASDAQ:EVAX) was provided by HC Wainwright & Co., and Evaxion Biotech reiterated their buy rating.
When was the last upgrade for Evaxion Biotech (EVAX)?
The last upgrade for Evaxion Biotech AS happened on April 2, 2024 when Ladenburg Thalmann raised their price target to $8. Ladenburg Thalmann previously had a neutral for Evaxion Biotech AS.
When was the last downgrade for Evaxion Biotech (EVAX)?
The last downgrade for Evaxion Biotech AS happened on December 21, 2023 when Ladenburg Thalmann changed their price target from N/A to N/A for Evaxion Biotech AS.
When is the next analyst rating going to be posted or updated for Evaxion Biotech (EVAX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evaxion Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evaxion Biotech was filed on April 2, 2025 so you should expect the next rating to be made available sometime around April 2, 2026.
Is the Analyst Rating Evaxion Biotech (EVAX) correct?
While ratings are subjective and will change, the latest Evaxion Biotech (EVAX) rating was a reiterated with a price target of $14.00 to $14.00. The current price Evaxion Biotech (EVAX) is trading at is $1.42, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.